166 related articles for article (PubMed ID: 6644793)
21. Suppression of monocyte dependent lymphocyte stimulation by sera from patients with Hodgkin's disease.
Holm G; Björkholm M; Mellstedt H; Nilsson P
J Clin Lab Immunol; 1982 Jan; 7(1):51-4. PubMed ID: 6461767
[TBL] [Abstract][Full Text] [Related]
22. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.
Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN
Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475
[TBL] [Abstract][Full Text] [Related]
23. Circulating immune complexes in Hodgkin's disease. Reactivity of IgG isolated from circulating immune complexes.
Nerurkar AV; Advani SH; Gothoskar BP
Neoplasma; 1993; 40(2):87-91. PubMed ID: 8350960
[TBL] [Abstract][Full Text] [Related]
24. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
Levo Y; Rotter V; Ramot B
Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
[TBL] [Abstract][Full Text] [Related]
25. Binding of soluble immune complexes in serum of patients with Hodgkin's disease to tissue cultures derived from the tumor.
Long JC; Hall CL; Brown CA; Stamatos C; Weitzman SA; Carey K
N Engl J Med; 1977 Aug; 297(6):295-9. PubMed ID: 559938
[TBL] [Abstract][Full Text] [Related]
26. PHA dose dependent defect in lymphocyte stimulation and E-rosette-forming cells in untreated Hodgkin's disease.
Land JM; Litwin J; Bigel P; Oberling F; Mayer S
Acta Haematol Pol; 1977; 8(2):131-4. PubMed ID: 329629
[TBL] [Abstract][Full Text] [Related]
27. Immunologic studies in patients with glomerulonephritis.
Belovezhdov N; Altankova I
Clin Nephrol; 1982 Mar; 17(3):141-8. PubMed ID: 7067176
[TBL] [Abstract][Full Text] [Related]
28. [Circulating immune complexes and immunologic reactivity in breast cancer].
Bilynskiĭ BT; Loginskiĭ VE; Fetsich TG
Eksp Onkol; 1984; 6(3):50-2. PubMed ID: 6333978
[TBL] [Abstract][Full Text] [Related]
29. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
30. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
31. Serum zinc levels, lymphocyte counts and functions in pediatric Hodgkin's disease.
Babacan E; Cavdar AO; Arcasoy A
Boll Ist Sieroter Milan; 1977 Jul; 56(3):228-34. PubMed ID: 901636
[TBL] [Abstract][Full Text] [Related]
32. Role of suppressor cells in depression of T lymphocyte proliferative response in untreated and treated Hodgkin's disease.
Han T
Cancer; 1980 Apr; 45(8):2102-8. PubMed ID: 6445226
[TBL] [Abstract][Full Text] [Related]
33. Presence of circulating immune complexes in patients with chronic lymphocytic leukaemia. Correlations between clinical and immunological features.
Mozzana R; Baldini L; Neri A; Cortelezzi A; Radaelli F; Colajori E; Polli EE
Boll Ist Sieroter Milan; 1982; 61(4):324-9. PubMed ID: 6927220
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic significance of typical immune reactions in myocardial infarction].
Zemskov AM; Alekhina OD; Zemskov VM; Zemskov MA; Zoloedov VI
Ter Arkh; 2008; 80(1):32-7. PubMed ID: 18326224
[TBL] [Abstract][Full Text] [Related]
35. Reversal of cell surface abnormalities of T lymphocytes in hodgkin's disease after in vitro incubation in fetal sera.
Fuks Z; Strober S; King DP; Kaplan HS
J Immunol; 1976 Oct; 117(4):1331-5. PubMed ID: 1086325
[TBL] [Abstract][Full Text] [Related]
36. Signals of monocyte activation in patients with SLE.
Kávai M; Zsindely A; Sonkoly I; Major M; Demján I; Szegedi G
Clin Exp Immunol; 1983 Feb; 51(2):255-60. PubMed ID: 6839541
[TBL] [Abstract][Full Text] [Related]
37. Evidence for the involvement of monocyte-derived toxic oxygen metabolites in the lymphocyte dysfunction of Hodgkin's disease.
Deshazo RD; Ewel C; Londono S; Metzger Z; Hoffeld JT; Oppenheim JJ
Clin Exp Immunol; 1981 Nov; 46(2):313-20. PubMed ID: 7337972
[TBL] [Abstract][Full Text] [Related]
38. Immune condition in patients with Hodgkin's disease.
Zywicka-Lopaciuk H; Konopka L; Traczyk Z; Pawelski S; Sylwestrowicz T; Maślanka K; Arczyńska-Brojer E; Cieśluk S; Karpowicz M; Małkowska-Zwierz W
Arch Immunol Ther Exp (Warsz); 1980; 28(1):153-60. PubMed ID: 6968189
[TBL] [Abstract][Full Text] [Related]
39. Elevated serum immune complex levels in Pogosta disease, an acute alphavirus infection with rash and arthritis.
Julkunen I; Brummer-Korvenkontio M; Hautanen A; Kuusisto P; Lindström P; Wager O; Penttinen K
J Clin Lab Immunol; 1986 Oct; 21(2):77-82. PubMed ID: 3029375
[TBL] [Abstract][Full Text] [Related]
40. E-rosette inhibiting substance in Hodgkin's disease spleen extracts.
Bieber MM; Fuks Z; Kaplan HS
Clin Exp Immunol; 1977 Sep; 29(3):369-75. PubMed ID: 201408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
